Science & Enterprise subscription

Follow us on Twitter

  • National Science Foundation is funding a new system that uses artificial intelligence to find optimal combinations…
    about 14 hours ago
  • New post on Science and Enterprise: NSF Funds AI Covid-19 Drug Combo Simulation #Science #Business
    about 14 hours ago
  • A spin-off enterprise from academic labs is raising $125 million for genetically edited pigs to produce organs for…
    about 14 hours ago
  • New post on Science and Enterprise: Gene-Edited Transplant Organ Company Raises $125M #Science #Business
    about 18 hours ago
  • A home Covid-19 test is being evaluated with a smartphone app, as part of an NIH program to quickly develop Covid-1…
    about 2 days ago

Please share Science & Enterprise

Pfizer, Biotech to Partner on Brown Fat Cell Research

Brown adipose tissue

Brown adipose tissue (Lucasmcorso/WikimediaCommons)

22 May 2014. BioRestorative Therapies Inc. in Jupiter, Florida and the pharmaceutical company Pfizer Inc. in New York are conducting a joint study of human brown fat tissue and cell lines, to discover more about their use as a platform for therapies for type 2 diabetes and obesity. Financial and intellectual property aspects of the deal were not disclosed.

BioRestorative Therapies is a biotechnology company developing therapies based largely on adult stem cells. The company’s portfolio includes stem cell-based treatments for bulging and herniated lumbar discs and cosmetic facial creams that aid in the production of proteins to delay skin aging. One of its products in development is ThermoStem, designed to treat diabetes and obesity with stem cells from brown adipose (fat) stem cells.

Brown fat in the body is linked with the maintenance and regulation of metabolism, and its main function is to transfer energy from food into heat. BioRestorative cites preclinical studies indicating a potential for brown fat to encourage weight loss, as well as reduce glucose and lipids (fats, oils) in the body, thus delaying the onset of type 2 diabetes. The company envisions developing ThermoStem into a small-molecule treatment for obesity and diabetes from brown fat stem cells, where the stem cells populate a bio-safe scaffold implanted into the patient.

The deal with Pfizer calls for a two-year joint study to identify and find out more about the metabolic functions of brown fat cells, leading to a human brown adipose cell model. Pfizer has a standing interest in partnering with other labs on weight-loss methods based on brown fat’s role in metabolism.

BioRestorative is also collaborating with University of Utah on its ThermoStem program. Utah provided BioRestorative with adipose tissue samples under a 2011 licensing agreement. And in 2012 the company engaged the services of Utah’s Amit Patel, a professor of regenerative medicine and tissue engineering, to conduct preclinical research leading to early-stage clinical trials of ThermoStem. Patel serves on BioRestorative’s science advisory board.

Read more:

*     *     *

Comments are closed.